Preview

Медицинский Совет

Расширенный поиск

Неалкогольная жировая болезнь печени: от научных достижений к клиническим алгоритмам

https://doi.org/10.21518/2079-701X-2013-10-46-51

Полный текст:

Аннотация

Неалкогольная жировая болезнь печени (НАЖБП) развивается при заболеваниях различной этиологии, объединяемых общим патоморфологическим феноменом: жировой инфильтрацией паренхимы печени с присоединением асептического воспаления и последующим фиброгенезом. В общей практике первичная НАЖБП имеет наибольшее значение как ранний маркер сахарного диабета 2 типа и высокого риска ССЗ, а также предиктор инсулинорезистентности и сахарного диабета 2 типа у больных морбидным общим или висцеральным ожирением и метаболическим синдромом. Учитывая клиническое и социальное значение ССЗ, проблема ранней диагностики и лечения НАЖБП требует координации усилий врачей всех специальностей.

Об авторе

Е. И. Вовк
МГМСУ им. А.И. Евдокимова
Россия


Список литературы

1. Harrison’s Principles of Internal Medicine, 17th ed.New York: McGraw-Hill Medical Publishing Division).

2. Гастроэнтерология. Национальное руководство / под ред. В.Т. Ивашкина, Т.Л. Лапина. М.: ГЭОТАР-Медиа, 2008. С. 626–632.

3. Bellentani S., Scaglioli F., Marino M., Bedogni G. Epidemiology of non–alcoholic fatty liver disease // Dig. Dis. 2010. №28. Р. 155–161.

4. Suzuki A., Angulo P., Lymp J., St. Sauver J., Muto A., Okada T., Lindor K. hronological development of elevated aminotransferases in a nonalcoholic population // HEPATOLOGY. 2005. №41(1). Р. 64–71.

5. Hamaguchi M., Kojima T., Takeda N. et al. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease // Ann. Intern. Med. 2005. №143(10). Р. 722–728.

6. Whalley S., Puvanachandra P., Desai A., Kennedy H. HEPATOLOGY outpatient service provision in secondary care: a study of liver disease incidence and resource costs // Clin. Med. 2007. №7(2). Р. 119–124.

7. Lee J.Y., Kim K.M., Lee S.G., Yu E., Lim Y.S., Lee H.C., Chung Y.H., Lee Y.S., Suh D.J. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center // J. Hepatol. 2007. №47(2). Р. 239–244.

8. Marcos A., Fischer R.A., Ham J.M., Olzinski A.T., Shiffman M.L., Sanyal A.J., Luketic V.A., Sterling R.K., Olbrisch M.E., Posner

9. M.P. Transplantation. 2000. №69. Р. 2410–2415.

10. Маев И.В., Дичева Д.Т., Лебедева Е.Г., Зайцева Е.В. Роль эссенциальных фосфолипидов в современных схемах лечения неалкогольного стеатогепатита // Гастроэнтерология. Приложение CONSILIUM MEDICUM. 2011. №1. С. 34–37.

11. Bellentani S., Pozzato G. et al. Clinical course and risk factors of hepatitis C virus related disease in the general population: report from the Dionysos study // Gut. 1999. №44 (3). Р. 874–880.

12. Williams C.D., Stenger J., Asike M.I., Torres D.M., Shaw J., Contreras M., Landt C.L., Harrison S.A. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study // Gastroenterology. 2011. №140. Р. 124–131.

13. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults // Aliment. Pharmacol. Ther. 2011. №34. Р. 274–285.

14. Frith J., Day C.P., Henderson E., Burt A.D., Newton J.L. Non-alcoholic fatty liver disease in older PEOPLE // GERONTOLOGY. 2009. №55(6). Р. 607–613.

15. Драпкина О.М., Корнеева О.Н. Неалкогольная жировая болезнь печени и сердечно-сосудистый риск: влияние женского пола. ФАРМАТЕКА, 2010, № 15, стр. 1-5.

16. Chalasani N, obair Younossi Z, Lavine J E. et al. The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. HEPATOLOGY, 2012, Vol. 55, No. 6, 2005-23.

17. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13(10):1579–84.

18. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006 Feb;43(2 Suppl 1):S99-S11.

19. Das U.N. Is obesity an inflammatory condition? Nutrtion. – 2001. – Vol. 17. – P.953-966.

20. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci

21. Драпкина О., Смирин В., Ивашкин В. Сахарный диабет как фактор риска неалкогольной жировой болезни печени. Врач. – 2010; №3: 7.

22. Драпкина О.М., Смирин В.И., Ивашкин В.Т. Патогенез, лечение и эпидемиология НАЖБП – что нового? Эпидемиология НАЖБП в России, Русский медицинский журнал, Болезни органов пищеварения, №28. 1717

23. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic Fatty Liver Disease Is Independently Associated With an Increased Incidence of Cardiovascular Events in Type 2 Diabetic Patients. Diabetes Care 2007;30(8):2119–21.

24. Ratziu V. et al. A proposal for current and future therapeutic strategies for NASH // EASL Special Conference «NAFLD/NASH and Related Metabolic Disease», Bologna, Italy, 2009. – Program and Abstracts. – P. 29.

25. Mohanty P., Ghanim H., Hamouda W., et al. Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells // Am. J. Clin. Nutr. – 2002. – Vol. 75. – P.767-772.

26. Ricci R. et al. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis // Science.– 2004. – Vol. 306. – P.1558-1561.

27. Wang S., Leonard S.S., Castranova V., et al. The role of superoxide radical in TNF-alpha induced NF-kappaB activation // Ann. Clin. Lab. Sci. – 199. – Vol. 29. – P.192-199.

28. Woronicz J.D., Gao X., Cao Z., et al. IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK // Science. – 1997. – Vol. 278. – P.866-869

29. Seo J.B. Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression // Mol. Cell. Biol. – 2004. – Vol. 24. – P.3430-3444.

30. Carroll M.F., Schade D.S. Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers //Circulation. – 2003. – Vol. 108. – P.24-31.

31. Nappo F., Esposito K., Cioffi M., et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals // J. Am. Coll.Cardio. – 2002. – Vol. l39. – P.1145-1150.

32. Oostrom A.J., Sijmonsma T.P., Verseyden C., et al. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction // J. Lipid Res. – 2003. – Vol. 44. –P.576-583.

33. Malhi H., Gores G. Molecular mechanisms of lipotoxicity in Nonalcoholic Fatty Liver Disease. Semin. Liver.Dis. – 2008; 28:360 – 369.

34. Маммаев С.Н., Багомедова Н.В., Богомолов П.О. и др. Цитокиновая система при неалкогольном стеатогепатите // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2007. – Т. 17, № 4. – С. 30–35.

35. Mohanty P., Hamouda W., Garg R., et al. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes // J. Clin. Endocrinol. Metab. – 2000. – Vol. 85. – P.2970-2973.

36. Aljada A., Ghanim H., Mohanty P. et al. Glucose intake induces an increase in AP-1 and Egr-1 binding activities and tissue factor and matrix metalloproteinase expressions in mononuclear cells and plasma tissue factor and matrix metalloproteinase concentrations // Am J Clin Nutr. – 2004. – Vol. 80. – P.51–57.

37. Kaneto H. et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide // Nat. Med. – 2004. – Vol. 10. – P.1128-1132.

38. Stulnig, Markus Berger, Michael Roden, Harald Sting. The FASEB Journal. Elevated serum free fatty acid concentrations inhibit T lymphocyte signaling. – 2000. – Vol. 14. – P.939-947.

39. Marschall H.-U. & Einarsson C. Gallstone disease. Journal of Internal Medicine 2007; 261; 529–542.

40. Dowling R.H. Review: pathogenesis of gallstones. Aliment Pharmacol Ther., 2000; 14 (Suppl): 39-47.

41. Лейшнер У. Практическое руководство по заболеваниям желчных путей.-М.: ГЭОТАР-МЕД, 2001.-264 с.

42. Kim JM, Lee HL, Moon W et al. Association between insulin, insulin resistance, and gallstone disease in Korean general population. Korean J Gastroenterol. 2007 Sep;50(3):183-7.

43. Méndez-Sánchez N, Bahena-Aponte J, Chávez-Tapia NC et al. Strong association between gallstones and cardiovascular disease. Am J Gastroenterol. 2005 Apr;100(4):827-30.

44. Chen CH, Huang MH, Yang JC et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults.J Clin Gastroenterol. 2006 Sep;40(8):745-52.

45. Dandona P, Aljada A, Chaudhuri A, et al. Metabolic Syndrome A Comprehensive Perspective Based on Interactions Between Obesity, Diabetes, and Inflammation Circulation. – 2005. – Vol. 111. – P.1448-1454.

46. Mudipalli A. Indian J Med Res, 2007, 126:518-527.

47. Simopoulos AP. Human requirement for Ω-3 polyunsaturated fatty acids.Poult Sci. 2000 Jul;79(7):961-70.

48. Mastellone I, Polichetti E, Grиs S. Dietary soybean phosphatidylcholine lowers lipidemia. Mechanisms at the levels of intestine, endothelial cell, and hepatobiliary axis. J Nutr Biochem, 2000, 11, 461–466.

49. LeBlanc MJ, Brunet S, Bouchard G et al. Effects of dietary soybean lecithin on plasma lipid transport and hepatic cholesterol metabolism in rats. J Nutr Biochem. 2003 Jan;14(1):40-8.

50. Lefebvre P, Cariou B, Lien F et al. Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation. Physiol Rev 2009; 89: 147–191,

51. Trauner M, Claudel T, Fickert P, et al. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis. 2010; 28(1):220-4.;

52. Keizman D. et al. Нarefuah.147(4):344-9,372.

53. Rodriguez-Leyva D. et al., The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid. Can J Cardiol. 2010 November; 26(9): 489–496.

54. Gaby AR. Nutritional approaches to prevention and treatment of gallstones. Altern Med Rev. 2009 Sep;14(3):258-67.

55. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Uusitupa M: Finnish Diabetes Study: prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance . N. Engl. J. Med. – 2001. – Vol. 344. –P.1343-1350.

56. Klein B, Platat C., Drai J., Oujaa M., et al. Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am. J. Clin. Nutr. – 2005 – Vol. 82. – P.1178 1184.

57. Kidd PM. Cell membranes, endothelia, and atherosclerosis – the importance of Phosphatidylcholine. Altern Med Rev 1996;1:148-167.

58. Mourad AM et al. Influence of Soy Lecithin Administration on Hypercholesterolemia. Cholesterol, Volume 2010, Article ID 824813.

59. Ma X., Zhao J., Lieber C.S. Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerate its regression. J. Hepatol.- 1996. – 24:604-13.

60. Watanabe A., Kobayashi M., Morishita N., Nagashima H. Multimodal treatement resulting in a rapid improvement of fatty liver disease in obese patients. Curr Ther. Res.- 1988.- 43:239-46.

61. Weber, P. C., and A. Leaf, 1991. Cardiovascular effects of omega-3 fatty acids.

62. Atherosclerosis risk factor modification

63. Kuntz E, Kuntz H-D: Гепатология, Учебное пособие и атлас , 3 издание Springer Press, Heidelberg 2008; глава 40., С.896.

64. Ревич Б.А., Авалиани С.Л., Тихонова Г.И. Экологическая эпидемиология / М.: Издательский центр «Академия», 2004. — 384 с.


Для цитирования:


Вовк Е.И. Неалкогольная жировая болезнь печени: от научных достижений к клиническим алгоритмам. Медицинский Совет. 2013;(10):46-51. https://doi.org/10.21518/2079-701X-2013-10-46-51

For citation:


Vovk E.I. Nonalcoholic fatty liver disease: from research success to clinical algorithms. Medical Council. 2013;(10):46-51. (In Russ.) https://doi.org/10.21518/2079-701X-2013-10-46-51

Просмотров: 73


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)